Using a collection of biobank CSF samples, we confirmed the S100A8/9 heterodimer is significantly up-regulated in AD patients relative to controls (Fig 6D) and therefore an excellent candidate to monitor the pharmacological activity of ORY-2001 in CSF in clinical trials. The gene discussed is S100A8; the disease is Alzheimer disease.